Call for proposals for Health Co-ordination activities H2020-HCO-2014 Closed!

Objectives

The Framework Programme for Research and Innovation (2014-2020) is implemented by specific programme and work programmes.

The “Societal challenges” responds directly to the policy priorities and societal challenges that are identified in the Europe 2020 strategy and that aim to stimulate the critical mass of research and innovation efforts needed to achieve the Union's policy goals.

The specific objective is to fully exploit the potential of Europe's talent pool and to ensure that the benefits of an innovation-led economy are both maximised and widely distributed across the Union in accordance with the principle of excellence.

Funding shall be focused on the following specific objectives:
(a) Health, demographic change and well-being.
(b) Food security, sustainable agriculture and forestry, marine, maritime and inland water research. and the bioeconomy.
(c) Secure, clean and efficient energy.
(d) Smart, green and integrated transport.
(e) Climate action, environment, resource efficiency and raw materials.
(f) Europe in a changing world - Inclusive, innovative and reflective societies.
(g) Secure societies - Protecting freedom and security of Europe and its citizens.

Actions

Actions foreseen within this call for proposals include the following topics:

  • HCO-01-2014: Support for the European Innovation Partnership on Active and Healthy Ageing. The strategic implementation plan (SIP) of the European innovation partnership on active and healthy ageing (EIP-AHA) has identified a number of priority action areas. In a subset of these, stakeholder action groups have developed action plans for implementing innovative services for the ageing population. Another subset of priority action areas addresses domains whose readiness towards implementation is maturing and may soon give rise to additional action plans. The EIP-AHA has invited, among others, the European Commission to establish favourable framework conditions to implement the actions outlined in the SIP. The European Commission, in its Communication "Taking forward the Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing", committed to take account of relevant priorities of the SIP, together with input from other stakeholders, for future research and innovation work programmes and instruments.
  • HCO-02-2014: Joint programming: Co-ordination action for the joint programming initiative (JPI) 'more years better lives the challenges and opportunities of demographic change'. Following the implementation of the actions foreseen by the Commission’s Communication on Joint Programming to tackle Europe’s major societal challenges, the Competitiveness Council has welcomed the progress made by EU Member States in Joint Programming Initiatives (JPIs) launched so far. Several Council Conclusions on Joint Programming invite the Commission to support JPIs via Coordination and Support Actions. The JPI "More Years, Better Lives - the Challenges and Opportunities of Demographic Change" enhances coordination and collaboration between national research programmes related to demographic change. It enables Member States to pursue common visions and a strategic research agenda on demographic change.
  • HCO-04-2014: Support for international infectious disease preparedness research. Human health worldwide is increasingly threatened by potential epidemics caused by existing, new and emerging infectious diseases, including those which are resistant to antimicrobial agents. An infectious epidemic can strike anywhere, and at any time globally. In order to save lives, the research response needs to be quick, flexible, comprehensive and global and therefore is beyond the capacity of any single country or even the European Union. Besides being a major threat to human health, such epidemics are a severe burden on the global economy with an impact on competitiveness, growth and jobs. In response to these challenges a global, multi-funder initiative has been launched, the global research collaboration for infectious disease preparedness (GloPID-R). Support is therefore required in building, maintaining and coordinating a global consortium of funding organisations working towards the goal of preparing for a rapid joint global research response to any new outbreak.
  • HCO-05-2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes. In the past twenty years the global death rate from diabetes has doubled and the World Health Organisation (WHO) is predicting that this will increase by two thirds by 2030. It is currently estimated that 347 million people worldwide suffer from diabetes with more than 80% from low-and middle-income countries. Of those suffering from diabetes, type 2 comprises 90% of this population around the world. Halting the rise in prevalence of diabetes has been identified as one of the 9 WHO non communicable diseases global voluntary targets to be met by Member States by 2025 With the burden of this chronic non-communicable disease ever-increasing the Global Alliance for Chronic Diseases (GACD) partnership, of which the Commission is a member, has agreed to launch a call for proposals on the prevention and treatment of type 2 diabetes, with a focus on implementation and intervention research in low- and middle-income countries and in vulnerable populations in high income countries.
  • HCO-07-2014: ERA-NET: Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020. The EU Joint Programming Initiative on Neurodegenerative Diseases Research, in particular Alzheimer's (JPND), was established in 2009 as the pilot of the Member State-led Joint Programming Initiatives and enables the participating EU Member States to work together on the challenge of age-related neurodegenerative diseases. JPND allows the establishment, alignment and building on of national research programmes to increase the effectiveness and impact of research efforts. The JPND Research Strategy must now be scaled-up and synergies must be established with Horizon 2020 as was also called for by the Council in its conclusions of 8 December 2011. The scope of the Research Strategy requires coordinated action not only amongst the participating countries but also with the EC for producing the necessary critical mass. Moreover, for achieving the highest impact possible, there is the need for less fragmentation, better coordination and alignment amongst the countries participating in the JPND.
  • HCO-08-2014: ERA-NET: Aligning national/regional translational cancer research programmes and activities. The challenges in the area of translational cancer research can only be met by an effective cooperation at transnational level avoiding the duplication of efforts, by ensuring the availability of critical mass, by efficiently using available resources, by exchanging knowledge, by producing more significant results of higher quality and impact, and sharing data and infrastructures. Significant progress has been made in this respect by existing initiatives. There is however still the need for better coordination, data sharing and alignment of national programmes and activities in the above mentioned area.
  • HCO-09-2014: ERA-NET: Systems medicine to address clinical needs. The rise of genomics and the accumulation of large amounts of data potentially provide medicine with many new opportunities. With this abundance of different types of data has come the realisation that a full understanding of disease processes requires research that integrates and interprets data at the system level. Through the seventh framework programme, co-ordination action CaSyM, health research funders, clinicians, researchers, medical educators and industry, have agreed a road map that prioritises areas where a systems approach is needed to address clinical questions and solve clinical problems. EU policy makers also recognise the need for systems medicine in the drive to make personalised medicine a reality (Commission draft report on use of –omics technologies in the development of personalised medicine).
  • HCO-10-2014: ERA NET rare disease research implementing IRDiRC objectives. Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 202. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.
  • HCO-14-2014: Bridging the divide in European health research and innovation. The research and innovation potential of the Member States remain very different, with large gaps between “innovation leaders” and “modest innovators”. This divide is equally present in Europen health research and innovation. Two major European instruments – the Research Framework Programme and the Structural Funds – attempt to address this issue, albeit from distinct perspectives, but with the same strategic goals of serving the Europe2020 strategy for smart, sustainable and inclusive growth.
  • HCO-15-2014: Mobilisation and mutual learning action plan. Ensuring that research and innovation in this societal challenge is not only excellent, but also relevant and responsive to the needs of all is important, not least in ensuring the uptake of results. HCO-16-2014: National contact points. Facilitate trans-national co-operation between NCPs within this societal challenge with a view to identifying and sharing good practice and raising the general standard of support to programme applicants, taking into account the diversity of actors that make up the constituency of this societal challenge.

European community funding

The Community provisional funding available for the call for proposals is:

  • 40,00 Million EUR (Global Budget)

All the important deadlines

  • 15 April 2014 - 5 years ago (Deadline for the presentation of proposals)

Further information about the call

Official webpage of the call

Useful documents

  • Health Co-ordination activities (Legal base)

Organisations eligible to participate

Opened to the following bodies or institutes with legal status established in the covered areas:

  • Any legal organisation

Covered areas

Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:

  • European Union (EU)

Directorate-Generale responsible

Directorate-General for Research

Related calls for proposals

Related calls

Explore other programmes